Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.date.accessioned | 2017-01-05T02:01:06Z | - |
dc.date.available | 2017-01-05T02:01:06Z | - |
dc.date.issued | 2008 | * |
dc.identifier.issn | 0378-5173 | * |
dc.identifier.other | OAK-4587 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/233613 | - |
dc.description.abstract | This study aimed to formulate and evaluate nasal delivery systems containing ondansetron hydrochloride. In the in vitro study, the permeation rate with the addition of 10% polyethylene glycol 300 (PEG 300) to aqueous solution containing 0.01% benzalkonium chloride (BC) and 10% sulfobutylether ß-cyclodextrin sodium salt (SBCD) was somewhat more rapid up to 1.5 h compared to the addition of 10% PG. The permeation flux increased as the drug concentration increased regardless of the vehicles used. The addition of nicotinamide or chitosan to aqueous drug solution (40 mg/ml) with 10% PEG 300 and 0.01% BC rather decreased permeation rate and delayed lag time. Even though cyclodextrins including SBCD or dimethyl-ß-cyclodextrin failed to show permeation enhancing effects of ondansetron hydrochloride, the addition of 10% SBCD to aqueous solution containing 10% PEG 300 and 0.01% BC could be a good candidate for ondansetron nasal delivery systems because of its safety profile, stable storage in refrigerator and solubilizing effect. With the above formulation, the nasal delivery system increased AUC0-2 h and Cmax by 2.1 and 1.7 times compared to those of oral delivery, respectively while there was no difference found in AUC0-2 h with intravenous administration. Therefore, the nasal delivery system of ondansetron hydrochloride formulated in this study was feasible for nasal administration. © 2007 Elsevier B.V. All rights reserved. | * |
dc.language | English | * |
dc.title | Formulation and evaluation of ondansetron nasal delivery systems | * |
dc.type | Article | * |
dc.relation.issue | 41276 | * |
dc.relation.volume | 349 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 101 | * |
dc.relation.lastpage | 107 | * |
dc.relation.journaltitle | International Journal of Pharmaceutics | * |
dc.identifier.doi | 10.1016/j.ijpharm.2007.07.028 | * |
dc.identifier.wosid | WOS:000252942400014 | * |
dc.identifier.scopusid | 2-s2.0-37349035788 | * |
dc.author.google | Cho E. | * |
dc.author.google | Gwak H. | * |
dc.author.google | Chun I. | * |
dc.date.modifydate | 20240123100124 | * |